As you know their is no 'i' in team, just like their is no 'i' in Nadolol. Really good summary W27, you are certainly a team player. You mentioned Pfizer and I think that company would make a nice fit for Invion. It was recently reported Pfizer had few bright spots in its autoimmune / immunology pipeline outside Xeliance (Jak inhibitor, successful phase 3 RA). Pfizer are trialling it in Lupus in phase 2 but it has side effects of high cholesterol and neutropenia. Pfizer's only other Lupus drug in phase 2 is PF - 04236921 and it crashed late last year. This would be dissapointing for a company who recently collaborated with a genetics company to run a Lupus trial in 2016 for 5,ooo effected people. Pfizer seem very committed to Lupus but don't have much in the cupboard outside 1 drug in phase 1,and Xeliance ( incidentally, whose phase 2 RA trial met primary endpoint ACR 59% Methotext (placebo) 35%, while our phase 2 trial in 75mg ACR 42% Methotext 30% ). In the Xeliance trial 4 people died, 1 because of the drug.
Did you know that Pfizer make our Lupus drug in Adelaide? In fact Dr Stan Bastiras Head R&D Hospira ( acquired by Pfizer Feb this year), recently published an abstract explaining the bioprocess they have developed to produce CPN10 ( Invion 103) for the current trials.
As for smoking cassation, Pfizer's Chantix is attracting lawsuits around the world and they don't have a ready replacement ( they have 1 drug in phase 1)
Our Dr Mitchell Glass is highly regarded in the US, he was invited to be a keynote speaker at the prestigous Boston Leaders conference in March on autoimmune diseases. Of the other 6 keynote speakers were Dr Peros Haguet ( Chief scientific officer Inflammation Pfizer), and Dr Martin Hodge ( Head of Translation Immuscience Pfizer). Lupuzor Chief CEO, Dr Zimmerman was also speaking.
Did you know that Brett Heading was Chairman of Chemgenix, and Dr Greg Collier CEO, when they sold the company to Cephalon?
I know a lot of people have written off Invion 103, but if we receive some good data on the 100mg dose, which I expect we will, look out because it will suppress Lupus Nehritis. Benlysta is the 1st drug to go through phase 3 Lupus and get FDA approval in 50 years, but doctors are searching for better drugs than this. Invion 103 has a novel different mechanism of action ( read W27 blog). Good exchange rate, very exciting times.
Expand
(20min delay)